Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Background: Achieving a functional or sterilizing cure for HIV will require identification of therapeutic interventions that reduce HIV reservoir size in infected individuals. Proteasome inhibitors, such as ixazomib, impact multiple aspects of HIV biology including latency, transcription initiation,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nathan W Cummins, Jason Baker, Rana Chakraborty, Patrick G Dean, Enrique Garcia-Rivera, Ashton Krogman, Shaji Kumar, Yury V Kuzmichev, Gregory M Laird, Alan Landay, Mathias Lichterfeld, Maryam Mahmood, Jeffrey Martinson, Mark Maynes, Sekar Natesampillai, Vincent Rajkumar, Yelizaveta Rassadkina, Kristen D. Ritter, Christina G Rivera, Stacey A Rizza, Krupa Subramanian, Aaron J Tande, Elizabeth R Wonderlich, Jennifer A Whitaker, John Zeuli, Andrew D Badley
Format:	article
Language:	EN
Published:	Elsevier 2021
Subjects:	HIV Latent reservoir Proteasome inhibitor Ixazomib Medicine (General) R5-920
Online Access:	https://doaj.org/article/9bcbc1806c0c4535bde930e29c873a95
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/9bcbc1806c0c4535bde930e29c873a95

Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Internet

Similar Items